Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Relaxin · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | 48 hour iv infusion of placebo |
| Relaxin | EXPERIMENTAL | 48 hour iv infusion of relaxin at 30 ug/kg/day |
| Name | Type | Description |
|---|---|---|
| Relaxin | DRUG | Intravenous infusion for 48 h at 30 ug/kg/day |
| Placebo | DRUG | Intravenous infusion for 48 h |
Inclusion Criteria: * Hospitalized for acute heart failure * Dyspnea at rest or with minimal exertion * Pulmonary congestion * Able to provide informed consent * Systolic blood pressure \> 125 mmHg * Impaired renal function defined as an eGFR of 30-75 mL/min/1.73m2 Exclusion Criteria: * Use of ot...
Relaxin is being studied for the treatment of congestive heart failure. It has been evaluated in Phase 2 clinical trials for acute heart failure and compensated heart failure. It is an investigational therapy and is not approved for any indication.
Relaxin is being developed by Novartis AG, which trades on the New York Stock Exchange under the ticker symbol NVS. Novartis is the sponsor of the clinical trials evaluating Relaxin in heart failure.
Relaxin is in Phase 2 clinical development. Two Phase 2 trials have been completed, and no active trials are currently recruiting. The program has enrolled a total of 1,179 participants across both studies.
Relaxin has been tested in two completed Phase 2 trials: NCT00520806, which enrolled 1,161 patients with acute heart failure in the United States and Israel, and NCT00259116, a pilot study of recombinant human Relaxin in 18 patients with compensated congestive heart failure in Germany.
No, Relaxin is not approved by the FDA. It remains an investigational drug in clinical development, with both Phase 2 trials completed. Approval would require successful completion of later-stage trials.